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Abstract
Death from stage 5 chronic kidney disease (CKD 5) in childhood or adolescence is rare, but something that all paediatric renal
physicians and most paediatricians will encounter. In this paper, we present the literature on three key areas of palliative care
practice essential to good clinical management: shared decision-making, advance care planning, and symptommanagement, with
particular reference to CKD 5 where kidney transplant is not an option and where a decision has been made to withdraw or
withhold dialysis. Some areas of care, particularly with regard to symptom management, have not been well-studied in children
and young people (CYP) with CKD 5 and recommendations with regard to drug choice and dose modification are based on adult
literature, known pharmacokinetics, and clinical experience.
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Introduction
The Renal Physicians Association identifies two groups of
children and young people (CYP) who may be considered
unsuitable for dialysis and transplant:
1. Those who, often due to complex multi-system disease or
co-morbidity, would not be suitable candidates for trans-
plant and where dialysis is considered a significant burden
without medium- to long-term benefit.
2. Those who have embarked on dialysis, but for whom
transplant is no longer (or has never been) an option,
where the burden of dialysis has become too great in
relation to potential benefit [1].
The Renal Physicians Association has also published guid-
ance for shared decision-making regarding the withholding
and withdrawing of dialysis in paediatric patients. These rec-
ommendations include:
1. Forgoing dialysis if initiating or continuing dialysis is
deemed to be harmful, of no benefit, or merely prolongs
a child’s dying process.
2. Consider forgoing dialysis in a patient with a terminal
illness whose long-term prognosis is poor if the patient
and family agree with the physician that dialysis would
not be of benefit or the burdens would outweigh the
benefit.
3. Consider the use of a time-limited trial of dialysis in neo-
nates, infants, children, and adolescents with acute kidney
injury (AKI) or stage 5 chronic kidney disease (CKD 5) to
allow for the assessment of extent of recovery from an
underlying disorder.
4. Develop a palliative care plan for all paediatric patients
with CKD 5 from the time of diagnosis and for children
with AKI who forgo dialysis [1].
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This article focuses on the palliative management of CYP
with CKD 5 where kidney transplant is not an option and
where a decision has been made to withdraw or withhold
dialysis. The recommendations made are based on published
literature combined with the clinical experience of a palliative
care team working in a large tertiary centre.
Shared decision-making and advance care
planning
When addressing significant kidney disease, professionals
must have an open and honest, age and developmentally ap-
propriate approach to communicating with CYP, working in
partnership with parents. Studies indicate that any approach to
discussion of the illness or management of care and treatment
should reflect all individuals, especially the CYP’s preference
for degree and timing of disclosure [2–4]. In circumstances
where withholding or withdrawing dialysis is being consid-
ered, discussions should involve a palliative care specialist,
where available, in addition to the renal physician, so the
family can be given a full understanding of all the options
for care [5]. In order to best support parental and CYP deci-
sion-making, it is important that they receive information
about life on dialysis, or with a transplant, and the feasibility
and likelihood of success [6], as well as what palliative man-
agement will involve, including what symptoms to expect,
and where and how these can be managed. Attention should
be given to the family’s thoughts on the impact of any inter-
vention, on the child, their family life, and on their child’s
prognosis, as well as what they consider the likely outcome,
what they would like to see happen, and what they think will
happen [7].
Enabling families to choose where and how they spend
their time is a key component of palliative care. Some may
choose a very hospital-focused approach to end of life care,
but others may want most of their care to be at home or in a
children’s hospice. If choosing to be at home, families will
need clear guidance with regard to symptom assessment, man-
agement, and medication administration, and will require ac-
cess to appropriate medication and equipment, 24-h palliative
care, and the support of teams in their own community (e.g.
children’s community nurses, family doctor, paediatrician).
After death, it may be possible for ongoing care to be provided
at home or in a hospice, regardless of where the CYP died, as
an alternative to a funeral home or mortuary. If families
choose for the CYP to move after death, transport plans
should be put in place in advance.
The presence of both palliative care and renal teams for
these discussions ensures continuity of care and joined-up
work, preventing families from feeling that the renal team
has ‘given up’ on their child. Both teams present together
assures the family in a concrete and substantive manner that
the child and family will not be abandoned, often a major
concern of parents [7].
These discussions are part of the advance care planning
process: a process in which the parents/CYP and clinical
teams discuss what the future may look like, the options avail-
able, and their priorities and goals [8]. It allows consideration
of medical interventions, resuscitation, place of death, and
care after death as well as wishes for life [8]. Decisions made
and wishes voiced should be clearly recorded, for example in
an advance care plan document such as the Children and
Young Person’s Advance Care Plan (www.cypacp.uk), and
shared with relevant professionals.
It is important to recognise that parents/CYP often strive to
keep their options open [8] and responses like ‘I’ll decide at
the time’ are not atypical. Advance care planning discussions
will usually, and appropriately, require a series of conversa-
tions over time, with plans reviewed and adapted as the CYP’s
condition changes.
Symptom management
CKD 5 is associated with a significant symptom burden. One
adult study reported over 50% of adult patients experienced
lack of energy, itch, drowsiness, dyspnoea, poor concentra-
tion, pain, poor appetite, swelling of arms/legs, and dry mouth
[9]. A study in children with CKD 5 reported pain in over 50%
and a high incidence (20–40%) of other symptoms, including
fatigue, nausea, dyspnoea, agitation, and pruritis [10].
Prevention of symptoms
Consideration should be given to management of blood pres-
sure, fluid balance, anaemia, acidosis, hyperkalaemia, magne-
sium, and phosphate. Any interventions require regular re-
view, incorporating the views of the CYP and parents, to
avoid continuing those that have no or minimal benefit, or
where the burden (such as hospital attendance) outweighs per-
ceived benefit.
Holistic management
A holistic approach to symptom management is essential, ad-
dressing psychological, social, and spiritual factors that influ-
ence symp tom expe r i ence and re sponse . Non-
pharmacological approaches such as massage, relaxation tech-
niques, and guided imagery should be used both alongside or
in place of medication. A psychologist and/or Child Life spe-
cialist should be part of the team caring for the CYP and
family and CYP should have opportunities to explore and
express their understanding, fears, and wishes through other
modalities such as art, music, or drama therapy.
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Medication dosing
CKD 5 significantly alters the effects of medications, promot-
ing potential toxicity [11]. Estimation of glomerular filtration
rates and creatinine clearance are the most common tools used
when determining appropriate dosing. However, this does not
account for the influence of tubular secretion or for the effects
of CKD 5 on pharmacokinetic variables such as absorption,
distribution, metabolism, and elimination [12].
Prescribers must be aware of potential toxicity and pre-
scribe according to a recognised formulary, such as the
Association for Paediatric Palliative Medicine Drug
Formulary [13], the British National Formulary for Children
(BNFc), or other relevant local or national formularies, and
make the recommended dose adjustments.
Recommendations in this article are based on a combina-
tion of existing evidence for dose modification, known phar-
macokinetic parameters, and clinical experience.
Pain (Table 1)
Pain is a common, often underestimated, symptom in CKD 5
[10, 31] and may include musculoskeletal, neuropathic, and
bone pain, as well as discomfort due to a renal mass or ascites.
Paracetamol is the non-opioid analgesic of choice. Non-
steroidal anti-inflammatory drugs (NSAIDs) should be
avoided, unless the benefits of therapy are deemed to out-
weigh risks.
Opioids have been poorly studied within paediatrics, par-
ticularly in CKD 5. Fentanyl, alfentanyl, and methadone ap-
pear to be the safest opioids, due to hepatic metabolism to
inactive metabolites [23, 32]. Fentanyl and alfentanyl uses
are limited by the lack of appropriate enteral formulations
and clinical experience. The complex pharmacokinetic profile
of methadone plus lack of experience outside specialist units
makes methadone a less than ideal choice. Hydromorphone,
not commonly used in the UK, is not recommended due to the
potential accumulation of neurotoxic metabolites [23].
However, we acknowledge that where clinicians are experi-
enced in the use of hydromorphone it could be used cautiously
on an ‘as needed’ basis.
Despite many reference sources suggesting the avoidance
of oxycodone or morphine, there is evidence to suggest care-
ful introduction and dosing may be safe and effective [14, 18],
particularly following bolus dose administration. Morphine
and oxycodone are therefore generally the opioids of choice
in paediatric CKD 5, particularly for enteral use. We recom-
mend increasing the dosing interval rather than reducing the
dose, to ensure adequate analgesia, but with sufficient time for
clearance to reduce accumulation. Risk of accumulation in-
creases with repeated doses; in this instance, dose reduction
may also be needed but should be titrated carefully to ensure
good analgesic effect.
Peripheral neuropathy and neuropathic pain are not unusu-
al in CKD 5 [33] but most medications commonly used to
treat neuropathic pain should be avoided or used at signifi-
cantly reduced doses.
Recommendations for management are given in Table 1.
Agitation (Table 2)
Agitation is often attributed to the accumulation of toxic me-
tabolites, but factors such as pain, breathlessness, fear, and
drug toxicity should be considered. Where medication is re-
quired, cautious use of haloperidol with dose reduction, or
levomepromazine with slow careful dose titration, is likely
to be the best option, although midazolam may have a role
in some situations.
Dyspnoea (Table 2)
Dyspnoea is most frequently due to infection, anaemia, or
pulmonary oedema. Interventions directed at treating an un-
derlying cause may be appropriate, alongside symptomatic
management. The benefits of fluid restriction may be limited
and an unnecessary burden, and diuretics may have limited
response. Blood transfusion can be burdensome and exacer-
bate fluid overload. For symptomatic relief, non-
pharmacological interventions, such as a hand-held fan direct-
ed at the face, can be effective [45]. An opioid should be the
first-choice medication, given at 25–50% of the dose used for
pain management [46] on an ‘as needed’ basis. Using midazo-
lam alongside an opioid may give additional benefit [47], but
this should be used cautiously.
Nausea and vomiting (Table 2)
Nausea and vomiting can result from raised urea levels and
metabolic disturbance, but also gastrointestinal fluid retention,
gastric stasis, reflux, pain, and anxiety. Allowing CYP to eat
‘little and often' or reducing nasogastric/gastrostomy feed vol-
umes may bring relief without recourse to medication. First-
choice anti-emetics are haloperidol, with dose reduction, or
levomepromazine, starting at a low dose and titrating up slow-
ly [40].
Metoclopramide is an option where gastric stasis is a factor,
but accumulation may occur in kidney impairment so dose
reduction is required [40, 41]. Ondansetron is safe for use,
without dose modification.
Pruritis (Table 2)
Regular skin care, using emollients, is essential. Phosphate
binders can be effective if phosphate levels are high. In
uraemic itch, antihistamines may have little benefit and low-
dose gabapentinoids are likely to be preferable [48]. The
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Alfentanyl No Safe without dose modification but use with caution.
Start at low dose and slowly titrate to effect, with
close monitoring.
Hepatic metabolism to inactive metabolites that are
cleared renally. 90% protein bound with only
unbound fraction able to cross into CNS.
Alterations in protein binding due to uraemia or reduced
plasma protein may lead to increases in unbound
fraction and CNS toxicity
Amitriptyline Possible Avoid 1st pass metabolism to nortriptyline, a more potent
metabolite that is renally excreted [14–17].Accumulation of metabolites may precipitate toxicity,
including cardiac arrhythmias [14, 15].
Fentanyl Possible Safe without dose modification but may accumulate
over time—use with caution
Hepatic metabolism to inactive metabolites. 10% of
parent drug excreted unchanged. Excreted in urine
and faeces [18].Start at low dose and slowly titrate with close





Yes For all routes, use with caution, starting at 50% dose
with either once daily or alternate day dosing. When
increasing the dose, consider maintaining extended
dosing interval, allowing sufficient time for clearance.
Renally cleared and excreted unchanged in the urine, so
potential for prolonged clearance in CKD 5 [19–22].
Hydromorphone Yes Not recommended. However, experienced clinicians
may choose to use cautiously, on an ‘as needed’ basis,
starting at the lowest recommended dose.
Hepatic metabolism to hydromorphone-3-glucoronide,
which is excreted in the urine [23].
Potential for accumulation and neurotoxicity.
Ketamine Yes Start at lowest usual recommended dose and titrate
according to response and toxicity.
Hepatic metabolism to norketamine, an active
metabolite with 20–30% the potency of ketamine [24,
25].Active metabolites may accumulate but not thought to
have significant clinical impact [24, 25]. Final clearance is in the urine and in bile [26].
Methadone Possible Safe but for use with extreme caution and close
monitoring, only under specialist supervision.
Approximately 20–50% excreted in urine as metabolites
or unchanged methadone [18, 23]. Protein binding to
alpha1-acid glycoprotein may be up-regulated, po-
tentially prolonging drug half-life [18, 27].
Start at the lowest recommended dose and slowly titrate
with close monitoring.
Time to steady state, analgesic efficacy, and toxicity
unpredictable.
Morphine Yes Use with caution on an ‘as needed’ basis, starting at
lowest recommended dose. Increase dose interval
rather than reducing the dose, to ensure adequate
analgesia with sufficient time for clearance. Risk of
accumulation with repeated doses may require dose
reduction, but titrate carefully to ensure adequate
analgesia.
Metabolites and approximately 10% of parent drug
(unchanged) rely on renal clearance [23].
Extreme caution if converting to long-acting oral prep-
aration.
Where continuous infusion needed, consider conversion
to another opioid with safer renal profile, e.g.
fentanyl.
Risk of accumulation of active metabolites which may





No Avoid—unsafe for use unless no other alternatives. Hepatic metabolism to inactive metabolites with less
than 10% of parent drug excreted unchanged in urine.Risk of worsening kidney function [27] and bleeding
due to platelet dysfunction [15, 27, 28]. No evidence to suggest safety of one NSAID over
another [15].
Oxycodone Yes Use with caution on an ‘as needed basis’, starting at
lowest dose and titrating slowly.
Hepatic metabolism to active metabolites, one of which
(noroxycodone) has an affinity for the opioid receptor
40× greater than oxycodone. Potential for accumula-
tion of metabolites and parent drug in renal impair-
ment but not thought clinically significant [18].
Extreme caution if converting to long-acting prepara-
tions.
Consider switch to fentanyl if continuous infusion
needed.
Isolated case reports of CNS toxicity and sedation.
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benefit of ondansetron is negligible [49]. Amongst the less
frequently used drugs, there is conflicting evidence for the role
of naltrexone [50, 51] but evidence for the benefit of thalido-
mide [52], which can be used without dose adjustment,
though experience of use in paediatrics is extremely limited
[53].
Fatigue
Fatigue may be due to or exacerbated by anaemia. For some,
regular transfusion may be appropriate, but this needs to be
considered against the burden of hospitalisation and need for
intravenous access, as well as the risk of fluid overload exac-
erbating dyspnoea. Maintaining haemoglobin with an eryth-
ropoiesis stimulator can be a helpful compromise, but will
have limited benefit in advancing disease. Practical ap-
proaches to managing fatigue should not be overlooked.
Maintaining a good day/night pattern, with activities during
the day and a good bedtime routine, is important. Good man-
agement of symptoms will aid undisturbed sleep, as well as
addressing anxieties and fears, which can often be exacerbated
overnight.
Secretions (Table 2)
As conscious levels reduce, CYP become less able to manage
oral secretions. Hyoscine hydrobromide crosses the blood–
brain barrier and may cause increased drowsiness, delirium,
or paradoxical agitation, particularly in CKD 5 where uraemia
increases the permeability of the blood–brain barrier [40].
Glycopyrronium (glycopyrrolate) is generally the drug of
choice, with dose reduction required and careful dose titration
[44]. Hyoscine butylbromide can also be used and is safe for
use in CKD 5 without dose reduction.
Key summary points
1. Decisions to commence or forgo dialysis and transplant
should be made jointly between the clinical teams, par-
ents, and, where appropriate, the CYP.
2. Advance care planning is the process through which cli-
nicians, parents, and CYP discuss and document their
priorities and goals for future care. It should include, but
not be limited to, agreement of treatment limitations.
3. CKD 5 is associated with a significant symptom burden
that includes pain, agitation, and dyspnoea. The preva-
lence of physical and psychological symptoms may be
greater than those in patients with advanced cancer.
4. CKD 5 significantly alters the effects of medications, of-
ten promoting toxicity; however, information regarding
the extent of dose reduction for many drugs is limited. It
is essential that prescribers are aware of potential toxicity,
prescribe using a recognised formulary, observe patients
closely, and adjust doses cautiously (considering both re-
ducing doses and increasing dosing intervals) in response
to effect and observed toxicity.
Multiple choice questions (answers are
provided following the reference list)
1. Advance care planning discussions
a) Should result in an agreement regarding resuscitation
and limitations of treatment.
b) Are often a series of conversations over a period of
time and decisions may change.
c) Must be led by a palliative care physician.
d) Should only involve the CYP in exceptional circum-
stances
2. When involving CYP in decision-making
a) Child/young person’s age is the most important
consideration.
b) Clinician shouldmeet with the child/young person alone.
c) Child/young person’s wishes should take precedence
over the wishes of parents.
d) Child/young person should determine degree and
timing of disclosure of information about care, treat-
ment, condition, and prognosis.
3. When selecting an opioid for pain management in CKD 5
a) Morphine should be avoided due to accumulation.





Paracetamol Possible Normal dosing but maintain a minimum of a 6-h interval
between doses.
Predominately hepatic metabolism to inactive
metabolites [28, 29]. Metabolites plus less than 10%
of parent drug (unchanged) excreted in urine.Potential for reduced excretion of metabolites, though
half-life of parent drug remains unaltered [30].
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Table 2 Summary of symptom management medication recommendations
Drug Recommendations Pharmacology
Opioid sensitive pain
Morphine Morphine, due to familiarity, is potentially a good option, given only
on as ‘as needed’ basis. Fentanyl or alfentanyl are potentially the







Gabapentin Gabapentinoids require dose adjustment and careful titration of dose
interval. Ketamine can be used without dose adjustment.





Haloperidol 50% dose reduction due to long half-life and potential for accumu-
lation [40]. Slow and considered dose titration in response to ef-
ficacy and toxicity.
Significant first-pass metabolism with oral absorption. Metabolites
not thought therapeutically relevant, although back conversion to
haloperidol has been described. 88 to 92% plasma protein bound
[34].
Levomepromazine Does not require dose reduction, but start at lowest recommended
dose, once daily, with slow cautious titration due to potential for
metabolite accumulation.
Hepatic metabolism with some clinically active metabolites that are
excreted renally and faecally, with less than 5% excreted
unchanged in the urine [35, 36].
There is limited data regarding dosing in CKD 5. Long half-life of 15 to 30 h, but duration of action reported to be
about 8 h [37].
Midazolam For bolus dosing, no dose reduction is necessary, as long as given on
an ‘as needed’ basis.
Hepatic metabolism to metabolites that are less active than the
parent compound [38].
For continuous infusion, commence at lowest recommended dose
and titrate slowly based on response.
Small amounts are excreted in urine unchanged [39].
96 to 97% protein bound, with significant distribution into tissue
[38].May accumulate due to reduced metabolite excretion and an increase
in free fraction through reduced protein binding [38].
Dyspnoea
Morphine Opioids at 25–50% of the dose used for pain. Morphine or
oxycodone can be used on an ‘as needed’ basis. Fentanyl or
alfentanyl are the preferred option for continuous infusions.
Midazolam may add benefit, but can exacerbate drowsiness and
delirium so ‘as needed’ dosing is preferable.
For opioids, see Table 1






See above under “Agitation” See above under “Agitation”
Metoclopramide Use at 50% dose reduction due to reduced renal clearance, with
accumulation and risk of extrapyramidal side effects [40, 41].
Hepatic metabolism to inactive metabolites, although about 20% is
excreted unchanged.
Studies have shown accumulation in kidney impairment, with
adverse effects, despite renal clearance accounting for a small
amount of total clearance [41].
Ondansetron No dose adjustment needed as it is converted to inactive metabolites,
with only small amounts excreted in the urine, so accumulation is
unlikely [42].
First-pass metabolism, with 60% bio-availability following oral ad-
ministration [43].
Hepatic metabolism to inactive metabolites with less than 5%
excreted in urine [42].
Pruritis
Gabapentin Gabapentinoids are likely to be the best options, with dose reduction






Avoid where possible due to potential CNS side effects.
Transdermal route less likely to be an issue but absorption may be
influenced by other complications of CKD 5, such as peripheral
oedema.
Uraemia may increase blood–brain barrier permeability leading to
increased drowsiness, delirium, or paradoxical agitation [40].
Hyoscine
butylbromide





50% dose reduction and careful titration in response to effect. Limited pharmacokinetic data available. Accumulation may occur
so caution with dosing is advised [44].
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c) Fentanyl or alfentanyl are the preferred option for a
continuous infusion.
d) The opioid dosing interval should generally be re-
duced.
4. When treating neuropathic pain in CKD 5
a) Ketamine should be used cautiously, with dose
reduction.
b) Gabapentin is safe to use without dose reduction.
c) Tricyclics can be used cautiously.
d) Pregabalin can be used but with dose reduction and a
long dosing interval.
5. The following medications can be used to manage
agitation
a) Haloperidol at 50% dose reduction.
b) Levomepromazine at lowest recommended starting
dose.
c) Bolus doses of midazolam, without dose reduction.
d) All of the above.
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